Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04263051
Title Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Centre Hospitalier Universitaire de Besancon
Indications

lung non-small cell carcinoma

Therapies

Nivolumab + UCPVax

Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST